Author Search Results

1

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)

by Aga Evgenia, Landay Alan, Pollard Richard B, Bosch Ronald J, Fox Lawrence, Mitsuyasu Ronald
Published 2010-08-01

Get full text

Article
2

VACUTAINER<sup>® </sup>CPT™ and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples

by Maino Vernon C, Mulder Candice B, Ruitenberg Joyce J, Landay Alan L, Ghanekar Smita A
Published 2006-05-01

Get full text

Article
3

Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen

by Kuritzkes Daniel R, Mildvan Donna, Landay Alan, Lederman Michael M, Marozsan Andre J, Baird Heather A, Kessler Harold A, Arts Eric J
Published 2005-04-01

Get full text

Article
4

Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics

by Li, Jonathan Z., Arnold, Kelly B., Lo, Janet, Dugast, Anne-Sophie, Plants, Jill, Ribaudo, Heather J., Cesa, Kevin, Heisey, Andrea, Kuritzkes, Daniel R., Lauffenburger, Douglas A., Alter, Galit, Landay, Alan, Grinspoon, Steven, Pereyra, Florencia
Published 2015

Call Number: Loading...
Located: Loading...

Get fulltext

Article
5

Potential inflammatory consequences in HIV controllers

by Martin Jeffrey N, Busch Michael P, Norris Philip J, Emu Brinda, Hatano Hiroyu, Martinson Jeffrey A, Landay Alan L, Hsue Priscilla Y, Sinclair Elizabeth, Hunt Peter W, Brooks Cecily, McCune Joseph M, Deeks Steven G
Published 2010-05-01

Article